BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- PMID: 18408761
- PMCID: PMC2748240
- DOI: 10.1038/onc.2008.109
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Abstract
Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2748240/bin/nihms-118663-f0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2748240/bin/nihms-118663-f0002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2748240/bin/nihms-118663-f0003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2748240/bin/nihms-118663-f0004.gif)
Similar articles
-
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Future Oncol. 2015 Sep;11(18):2525-40. doi: 10.2217/fon.15.183. Epub 2015 Aug 28. Future Oncol. 2015. PMID: 26314834 Review.
-
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.BioDrugs. 2015 Jun;29(3):167-83. doi: 10.1007/s40259-015-0130-9. BioDrugs. 2015. PMID: 26123538 Free PMC article. Review.
-
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.Cancer Discov. 2012 Oct;2(10):922-33. doi: 10.1158/2159-8290.CD-12-0108. Epub 2012 Sep 5. Cancer Discov. 2012. PMID: 22956644 Free PMC article.
-
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.Int J Cancer. 2012 May 15;130(10):2445-54. doi: 10.1002/ijc.26276. Epub 2011 Aug 24. Int J Cancer. 2012. PMID: 21732342
-
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.Mol Cancer Ther. 2010 Jun;9(6):1647-56. doi: 10.1158/1535-7163.MCT-09-1009. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530710
Cited by
-
Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR.ACS Med Chem Lett. 2024 Apr 5;15(5):583-589. doi: 10.1021/acsmedchemlett.3c00425. eCollection 2024 May 9. ACS Med Chem Lett. 2024. PMID: 38746885
-
A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.Neurooncol Adv. 2024 Mar 30;6(1):vdae049. doi: 10.1093/noajnl/vdae049. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38680990 Free PMC article.
-
Bilateral keratitis associated with afatinib therapy.Taiwan J Ophthalmol. 2024 Feb 23;14(1):121-124. doi: 10.4103/tjo.TJO-D-24-00003. eCollection 2024 Jan-Mar. Taiwan J Ophthalmol. 2024. PMID: 38654991 Free PMC article.
-
A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase.bioRxiv [Preprint]. 2024 Apr 10:2024.04.08.587960. doi: 10.1101/2024.04.08.587960. bioRxiv. 2024. PMID: 38645018 Free PMC article. Preprint.
-
Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy.Molecules. 2024 Mar 23;29(7):1448. doi: 10.3390/molecules29071448. Molecules. 2024. PMID: 38611728 Free PMC article. Review.
References
-
- Bedano PM, Hanna NH. Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006;1:582–587. - PubMed
-
- Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132–1139. - PubMed
-
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043. - PubMed
-
- Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98:80–85. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P20 CA090578/CA/NCI NIH HHS/United States
- K08 AG024004/AG/NIA NIH HHS/United States
- R01 CA122794/CA/NCI NIH HHS/United States
- P20 CA90578/CA/NCI NIH HHS/United States
- R01 CA90687/CA/NCI NIH HHS/United States
- R01 CA122794-04/CA/NCI NIH HHS/United States
- P50 CA090578/CA/NCI NIH HHS/United States
- R01 CA090687/CA/NCI NIH HHS/United States
- P50 CA090578-06/CA/NCI NIH HHS/United States
- R01 AG2400401/AG/NIA NIH HHS/United States
- R01 AG027757-03/AG/NIA NIH HHS/United States
- R01 AG027757/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous